Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinopharm COVID-19 vaccine + Sinovac COVID-19 vaccine
- Development stage
- Phase 2
- Lead developer
- Sinopharm
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to the use of inactivated whole-virus COVID-19 vaccines, specifically Sinopharm's BBIBP-CorV and Sinovac's CoronaVac, within the context of clinical research conducted by the Victoria Biomedical Research Institute. These vaccines are produced by growing SARS-CoV-2 in Vero cells, followed by chemical inactivation with beta-propiolactone and adsorption onto an aluminum hydroxide adjuvant. This traditional vaccine platform presents the immune system with the entire structural repertoire of the virus, including the spike, nucleocapsid, and membrane proteins, in a non-replicating form. In the referenced Phase 2b trial (NCT05327114), these vaccines are evaluated as part of homologous or heterologous boosting regimens in adolescents and adults with and without HIV infection in Kenya, the Democratic Republic of Congo, and Rwanda.
- Brand names
- Hayat-VaxCoronaVac
- Other names
- Inactivated Sinopharm or Sinovac COVID-19 vaccineBIBP vaccineSinopharm vaccineSinovac vaccineInactivated SARS-CoV-2 vaccine (Vero Cell)
02
Targets
E (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)N (Nucleocapsid protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on Sinopharm COVID-19 vaccine + Sinovac COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinopharm COVID-19 vaccine + Sinovac COVID-19 vaccine.